US researchers report blood test that can predict Alzheimer’s

10 March 2014

A blood test that can accurately predict the onset of Alzheimer's disease has been reported by, US researchers. They showed that testing levels of 10 fats in the blood could predict - with 90% accuracy - the risk of the disease coming on in the next three years.

Their findings, published in Nature Medicine, will now be tested in larger clinical trials.

Scientists at Georgetown University in Washington DC analysed blood samples from 525 people over the age of 70 as part of a five-year study. They took 53 of them who developed Alzheimer's or mild cognitive impairment and compared their blood with 53 who stayed mentally agile. They found differences in the levels of 10 lipids, or fats, between the two groups. And when the research team looked in the other blood samples, those 10 markers of Alzheimer's could predict who was likely to enter mental decline in the following years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical